Fundraising FoxNovo Holdings — 2021 Investments
12 investments dated 2021 · listed companies and verified rows first · show all
Disc Medicine is a biopharmaceutical company developing therapies from discovery through clinical development for patients in need.
BiotechHealthtech
John Quisel(Chief Executive Officer)inJean Franchi(Chief Financial Officer)inJonathan Yu(Chief Operating Officer)inWill Savage(Chief Medical Officer)inPamela Stephenson(Chief Commercial Officer)inSteve Caffé(Chief Regulatory Officer)in
Co-investorsAccess BiotechnologyAtlas VentureBain Capital Life SciencesForesite CapitalFrazier Life SciencesHercules Capital, Inc.+8 more
Esco Lifesciences manufactures laboratory equipment, biopharma devices, and IVF medical equipment for clinical, research, and industrial laboratories across more than 100 countries.
Advanced ManufacturingBiotechHardwareHealthtechMedical DevicesSingapore, SG
Lim Lay Yew(Founder)inLow Yae Foong(Founder)
Co-investorsVivo CapitalGIC
Revenue cycle management platform and electronic clearinghouse
HealthtechJacksonville, US
Nathan W. Eastman(Chief Financial Officer, Treasurer)inChristopher Hunter(Director)Steve Betts(Director)Earnie Franklin(Director)Aaron Gani(Director)Carl McDonald(Director)
Board seatAbhijeet Lele· per SEC Form D
Co-investorsFrancisco Partners
Genomatica (Geno) develops biotechnology processes to produce bio-based chemicals and materials—such as 1,4-butanediol (BDO), butylene glycol for cosmetics, and plant-based nylon—as alternatives to fossil-fuel-derived inputs.
BiotechCircular EconomyCleantechClimate TechNew MaterialsSan Diego, US
Christophe Schilling(Co-founder (former CEO))inBernhard Palsson(Co-founder)Carlos A. Cabrera(Executive Chairman)inJohn G. Gugel(Chief Executive Officer)inTom McDonald(SVP, Finance & Chief Financial Officer)inNelson Barton(SVP, Research and Development)in
Board seatAnders Bendsen Spohr· per SEC Form D
Co-investorsThule InvestmentsVantagePoint Capital PartnersViking GlobalCasdin CapitalDraper Fisher Jurvetson (DFJ)Mohr Davidow Ventures
Arcellx develops CAR T-cell therapies that are individually designed for each patient, using the immune system to target and attack cancer.
BiotechHealthtechGaithersburg, US
Han Lee(Executive Officer)Rami Elghandour(Executive Officer, Director)in
BoardJill Carroll(Director)inAli Behbahani(Director)inDerek Yoon(Director)inTiba Aynechi(Director)in
Co-investorsLG Technology VenturesNew Enterprise Associates (NEA)Quan CapitalSamsara BioCapitalSixty Degree CapitalSolasta Ventures+5 more
Asgard provides sales intelligence and intent detection data to B2B companies, identifying qualified prospects and their specific needs for targeted sales outreach and account-based marketing campaigns.
AI & Machine LearningData & InfrastructureEnterprise SoftwareSales TechParis, FR
Co-investorsTechstarsBoehringer Ingelheim Venture FundIndustrifondenRobot Ventures
Asgard Therapeutics develops direct cell reprogramming technologies that convert cancer cells into dendritic cells to restore anti-cancer immune responses.
AI & Machine LearningBiotechHealthtechMedical DevicesLund, SE
Cristiana Pires(Co-founder and CEO)inFábio Rosa(Co-founder and VP of Research)inFilipe Pereira(Co-founder and Head of Innovation)in
Co-investorsIndustrifondenLU InnovationRV Invest GmbHBoehringer Ingelheim Venture Fund
Cyteir is a clinical-stage oncology company developing CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters.
BiotechHealthtechCambridge, US
Kevin Mills(Executive Officer, Director)inRonald Goldstein(Executive Officer)inDonald Corcoran(Executive Officer, Director)inMarkus Renschler(Director)in
BoardTimothy Romberger(Director)Barry Mills(Director)
Co-investorsDroia VenturesLightstone VenturesOUP (Osage University Partners)Shah Family OfficeAlly Bridge GroupDe Novo Ventures+3 more
OLG Machinery, founded in 2008, trades new and certified used industrial spare parts and machinery, serving U.S. companies operating across North and South America with a focus on Mexico.
Advanced ManufacturingB2B MarketplacesLogistics & Supply Chain
Co-investorsOxford Investment Opportunity Network (OION)Ally Bridge GroupAltium CapitalAmgen VenturesDroia VenturesFrazier Healthcare Partners+2 more
Hummingbird Bioscience is a precision biotherapeutics company developing a pipeline of novel targeted therapies for cancer, using proprietary drug discovery technologies and platforms.
AI & Machine LearningBiotechDeep TechHealthtech
Piers Ingram(Chief Executive Officer, Co-Founder, Executive Director)inJerome Boyd-Kirkup(Chief Scientific Officer, Co-Founder)inKonrad Paszkiewicz(Chief Technology Officer)inKwek Kon Yew(Chief Medical Officer)Dipti Thakkar(Chief Operating Officer)in
Co-investorsAltium CapitalClavystBioDecheng CapitalDroia VenturesFrazier Life SciencesKiwoom Investment+6 more
Numab develops multispecific antibody-based therapeutics using its proprietary λ-Cap and MATCH discovery and engineering platforms, aiming to improve on first-generation antibody therapies in potency, stability, effect duration, and safety.
BiotechDeep Tech
David Urech(Founder)in
Co-investorsEisai Innovation, Inc.HBM Healthcare InvestmentsHBM PartnersBiotechnology Value FundBlackRockForbion+1 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.